United States · 
What does BioAdvance invest in?
BioAdvance invests most often at Series A and Series B (73% of the rounds on record), in sectors such as Life-science, Biotech and Pharmaceutical.
BioAdvance highlights
- 01
23 rounds on record
- 02
Mostly Series A and Series B: 73% of its rounds
- 03
Sole investor in 2 rounds, median $500K
- 04
8 exits from the portfolio
What they do
BioAdvance Capital invests in early-stage, life-science companies in the Mid-Atlantic Region with the potential to enhance human well-being & quality of life.From their own website
- Type
- VC firm
- Cheque size
- Not stated
- Stages
- SeedSeries A
- Sectors
- Life-scienceBiotechPharmaceutical
- Based in
- Conshohocken, United States
- Cold pitches
- Not accepted
The record
Every round we can evidence, newest first23 appearances
- 2023
1 round
- Nov
- 2019
2 rounds
- Aug
- May
- 2018
1 round
- Dec
- 2017
1 round
- Aug
- 2015
2 rounds
- Jun
- Feb
- 2014
1 round
- Mar
- 2013
1 round
- Mar
- 2012
3 rounds
- Aug
- Jul
- Jun
- 2009
1 round
- May
- 2008
1 round
- Jul
- 2007
2 rounds
- May
- Apr
- 2006
2 rounds
- Nov
- Jan
- 2005
4 rounds
- Aug
- Jul
- Jan
- Jan
- 2004
1 round
- Oct
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
We hold 10 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What they claim to have backed
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed8 in all
Novira TherapeuticsBought by Johnson & JohnsonUndisclosedNov 2015
NuPatheBought by Endo Health Solutions$105MDec 2013
Ceptaris TherapeuticsBought by Actelion Pharmaceuticals$250MJul 2013
Acuity PharmaceuticalsBought by OPKO HealthUndisclosedJun 2011
Avid RadiopharmaceuticalsBought by Eli Lilly$800MNov 2010
NuPatheListedUndisclosedAug 2010
Immune ControlBought by Corridor PharmaceuticalsUndisclosedJun 2010
Protez PharmaceuticalsBought by Novartis$400MJun 2008
An exit counts when it came after the firm's first round in the company. From historical deal records.